Rheumatoid Arthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or have an inadequate response, the U.S. market is crowded with efficacious biologics and targeted oral therapies, including blockbuster TNF-alpha inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and non-TNF-alpha inhibitors, such as Bristol Myers Squibb’s Orencia and Roche’s Actemra and the oral JAK inhibitors Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). Indeed, the FDA’s approval of Rinvoq led to increased competition within the JAK inhibitor class and among the non-TNF biologics. However, the recent extension of the FDA’s safety warnings to the entire JAK class will likely impact the overall use of these drugs, leading to increased uptake of other targeted agents.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed RA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed RA patients?
- How have JAK inhibitors been integrated into the treatment algorithm, and what is their source of business?
- What percentage of RA patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?
- What percentage of RA patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Amgen, Biogen, BMS, Eli Lilly, Janssen, Pfizer, Roche, Regeneron, Sanofi, UCB.
Key drugs: Actemra, biosimilar infliximab, Cimzia, Enbrel, Humira, Kevzara, Olumiant, Orencia, Remicade, Rinvoq, Rituxan, Simponi, Simponi Aria, Xeljanz.
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more-detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
- Rheumatoid Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Rheumatoid Arthritis US May, 2023
- Treatment Algorithms CDA Rheumatoid Arthritis US May 2023
Sheema Kher, M.Pharm., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kher has much experience in the U.S. market access and payer landscape and has analyzed formulary and payer restrictions in multiple therapy areas for diverse lines of business, including commercial, HIX, managed Medicaid, state Medicaid, and Medicare. She holds a master’s degree in drug regulatory affairs from Amity University in Noida.